A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation, ...

Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be ...

Despite all that, there are some good reasons to consider buying into Novo Nordisk -- and the best is its low valuation, given its growth potential. The stock's recent price-to-earnings (P/E) ratio of ...

Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, ...

Lilly has the edge on Danish rival Novo to weather potential U.S. price cuts on its blockbuster obesity drug Zepbound, backed ...

Some investors may welcome the Novo Nordisk Foundation’s sweeping moves to accelerate a strategy shift. Yet the speed and ...

Novo Nordisk's top investor moved to take control of the drugmaker's board on Tuesday, vowing a sharper focus on the key U.S.

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's ...

Novo Nordisk to reshuffle its board after a clash with its largest shareholder over governance changes. Read more here.

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...

Karen Finerman, CEO & Co-founder, Metropolitan Capital Advisors, said in a recent program on CNBC that she likes NVO amid the ...

The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat Type 2 diabetes ...